,trastuzumab deruxtecan
astrazeneca,medsir,daiichi sankyo
['mbc', 'breast', 'destiny-breast04', 'medsir']
what a great milestone for destiny-breast04!
a significantly longer pfs (9.9 vs 5.1 mo, hr0.50) and os (23.4 vs 16.8 mo, hr0.64) for t-dxd vs standard chemo in pretreated her2-low mbc. excited to see these results in today's plenary session at #asco22! 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc